<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01938781</url>
  </required_header>
  <id_info>
    <org_study_id>2013ZX10002004-1</org_study_id>
    <nct_id>NCT01938781</nct_id>
  </id_info>
  <brief_title>Optimized Treatment and Regression of HBV-induced Liver Fibrosis</brief_title>
  <official_title>Optimized Treatment and Regression of HBV-induced Liver Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sir Run Run Shaw Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing YouAn Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing 302 Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Hospital of Shijiazhuang City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Logistics University of Chinese People's Armed Police Forces</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Shanxi Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Yanbian University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with chronic hepatitis B histologically confirmed of liver fibrosis S2/S3 (similar
      to metavir F2/F3, Ishak 2/3/4) are randomly assigned in a 1:1 ratio. One arm is entecavir
      alone for 2 years; the other is entecavir alone for the first 0.5 year, entecavir plus
      pegylated interferon (peg-IFN) for 1 year, entecavir for another additional 0.5 year.
      Patients will be assessed at baseline, at every six months for blood count, liver function
      test, HBVDNA, AFP, prothrombin time, thyroid function, liver ultrasonography, and Fibroscan.
      The second liver biopsy will be performed to evaluate regression rate of liver fibrosis 1.5
      years after initial therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regression Rate of HBV-induced Liver Fibrosis</measure>
    <time_frame>1.5 to 2 years</time_frame>
    <description>Fibrosis regression of 1 point by Ishak scoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBVDNA undetectable rate</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>The HBVDNA undetectable rate after 1 year and 2-year treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibroscan scores</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Fibroscan scores after 1 and 2-year treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life Quality</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Life quality after 1 and 2-year treatment by SF-36 and EQ-5D questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of drug resistance</measure>
    <time_frame>1 year and 2 years</time_frame>
    <description>Incidence of drug resistance after 1 and 2-year treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Liver Fibrosis</condition>
  <arm_group>
    <arm_group_label>Entecavir monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>entecavir, 0.5mg, qd, oral, for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Entecavir plus peg-IFN Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>entecavir combined peg-IFN in the middle 1 year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entecavir</intervention_name>
    <description>antiviral therapy</description>
    <arm_group_label>Entecavir monotherapy</arm_group_label>
    <arm_group_label>Entecavir plus peg-IFN Therapy</arm_group_label>
    <other_name>entecavir dispersible tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peg-IFN</intervention_name>
    <description>antiviral and antifibrosis therapy</description>
    <arm_group_label>Entecavir plus peg-IFN Therapy</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Ages from 18 to 65 years old;

          2. Male or female;

          3. Treatment-naive patients with chronic HBV-induced fibrosis S2/S3 (similar to F2/F3,
             Ishak 2/3/4), who consent to undergo liver biopsy before and after treatment;

          4. Patients with HBeAg-positive, HBVDNA&gt;2×10&lt;4&gt; IU/ml or with HBeAg-negative,
             HBVDNA&gt;2×10&lt;3&gt; IU/ml;

          5. Agree to be follow-up regularly;

          6. signature of written inform consent.

        Exclusion Criteria:

          1. Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy,
             esophageal varices bleeding or other complications of decompensated cirrhosis or
             hepatocelluar carcinoma;

          2. Patients who are allergic to entecavir, interferon, or their components, and those
             considered not suitable for medications used in this study;

          3. Patients coinfection with HCV or HIV, alcoholic liver disease, autoimmune liver
             disease, genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty
             liver disease or other chronic liver diseases;

          4. Patients with baseline AFP level higher than 100 ng/ml and possible malignant lesion
             on image, or AFP level higher than 100 ng/ml for continuous three months;

          5. Creatinine &gt;1.5×ULN;

          6. Patients with other uncured malignant tumors;

          7. Patients with severe diseases of heart, lung, kidney, brain, blood system or other
             organs;

          8. Patients with severe neurological or psychological disease (e.g. epilepsy, depression,
             mania and schizophrenia);

          9. Patients with poorly controlled diabetes, hypertension or thyroid disease;

         10. Patients with any other reasons not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong You, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100015</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>302 Military Hospital Of China</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Friendship Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing YouAn Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Uiversity</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100871</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shijiazhuang Fifth Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science ＆Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>300030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Yanbian University</name>
      <address>
        <city>Yanji</city>
        <state>Jilin</state>
        <zip>133000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renji Hospital, Shanghai Jiao Tong University, School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huashan Hospital FuDan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital Affiliated to Logistics University of Chinese People's Armed Police Force</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300162</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 5, 2013</study_first_submitted>
  <study_first_submitted_qc>September 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2013</study_first_posted>
  <last_update_submitted>July 26, 2018</last_update_submitted>
  <last_update_submitted_qc>July 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Hong You</investigator_full_name>
    <investigator_title>Vice-Director of Liver Research Center</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>Liver fibrosis</keyword>
  <keyword>Regression</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

